Agent Orange Exposure Does Not Modify the Rate of Developing Certain Service-Connected Cancers in U.S. Veterans with Monoclonal Gammopathy of Undetermined Significance.

INTRODUCTION: Agent Orange (AO) exposure has been associated with increased risk of monoclonal gammopathy of undetermined significance (MGUS), the precursor of multiple myeloma, as well as certain hematologic and solid malignancies in U.S. military personnel. However, the association between AO exposure and subsequent cancers among Veterans with a prior diagnosis of MGUS has not been examined. MATERIALS AND METHODS: The source of subjects were US Veterans diagnosed with MGUS in the national Veteran Health Administration system between 1988 and 2024. A retrospective cohort analysis using multivariable Cox proportional hazards models was employed to evaluate the association between AO exposure and developing certain service-connected cancers after MGUS diagnosis, adjusting for age at MGUS diagnosis, sex, military branch, and tobacco use. Results were reported as adjusted hazard ratios (aHR) with 95% confidence intervals (CI). RESULTS: Subsequent cancers occurred in 850 out of 3,246 patients (26%) during the study period with a median follow-up of 5.2 years. AO exposure was not associated with a higher rate of cancers overall (aHR, 0.95; 95% CI, 0.79-1.15; P = .60), or specific service-connected cancers, such as plasma cell neoplasms (aHR, 1.07; 95% CI, 0.78-1.47; P = .69), respiratory cancer (aHR, 0.86; 95% CI, 0.55-1.34; P = .50), prostate cancer (aHR, 1.05; 95% CI, 0.69-1.62; P = .81), and lymphoma (aHR, 1.10; 95% CI, 0.63-1.93; P = .73). Bladder cancer and soft tissue sarcoma had insufficient counts for stable model-based estimation and are reported descriptively only. CONCLUSIONS: Prior AO exposure was not associated with an increased rate of subsequent service-connected cancers in Veterans diagnosed with MGUS over a median follow-up of 5.2 years. These findings underscore the need for improved exposure data collection within military personnel cohorts to facilitate discovery of military-specific cancer risk factors.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1093/milmed/usag515
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Agent Orange Exposure Does Not Modify the Rate of Developing Certain Service-Connected Cancers in U.S. Veterans with Monoclonal Gammopathy of Undetermined Significance.

Wendy Cozen, Helen Ma, Jia Yi Wan, Pankaj Gupta et al.
PubMed
Multiple Myeloma Research and Treatments
article

Agent Orange Exposure Does Not Modify the Rate of Developing Certain Service-Connected Cancers in U.S. Veterans with Monoclonal Gammopathy of Undetermined Significance.

Wendy Cozen, Helen Ma, Jia Yi Wan, Pankaj Gupta, Lu He
article en

Abstract

INTRODUCTION: Agent Orange (AO) exposure has been associated with increased risk of monoclonal gammopathy of undetermined significance (MGUS), the precursor of multiple myeloma, as well as certain hematologic and solid malignancies in U.S. military personnel. However, the association between AO exposure and subsequent cancers among Veterans with a prior diagnosis of MGUS has not been examined. MATERIALS AND METHODS: The source of subjects were US Veterans diagnosed with MGUS in the national Veteran Health Administration system between 1988 and 2024. A retrospective cohort analysis using multivariable Cox proportional hazards models was employed to evaluate the association between AO exposure and developing certain service-connected cancers after MGUS diagnosis, adjusting for age at MGUS diagnosis, sex, military branch, and tobacco use. Results were reported as adjusted hazard ratios (aHR) with 95% confidence intervals (CI). RESULTS: Subsequent cancers occurred in 850 out of 3,246 patients (26%) during the study period with a median follow-up of 5.2 years. AO exposure was not associated with a higher rate of cancers overall (aHR, 0.95; 95% CI, 0.79-1.15; P = .60), or specific service-connected cancers, such as plasma cell neoplasms (aHR, 1.07; 95% CI, 0.78-1.47; P = .69), respiratory cancer (aHR, 0.86; 95% CI, 0.55-1.34; P = .50), prostate cancer (aHR, 1.05; 95% CI, 0.69-1.62; P = .81), and lymphoma (aHR, 1.10; 95% CI, 0.63-1.93; P = .73). Bladder cancer and soft tissue sarcoma had insufficient counts for stable model-based estimation and are reported descriptively only. CONCLUSIONS: Prior AO exposure was not associated with an increased rate of subsequent service-connected cancers in Veterans diagnosed with MGUS over a median follow-up of 5.2 years. These findings underscore the need for improved exposure data collection within military personnel cohorts to facilitate discovery of military-specific cancer risk factors.

PubMed
University of Washington (US), University of California, Irvine (US), Tibor Rubin VA Medical Center (US), UC Irvine Health (US), UC Irvine Chao Family Comprehensive Cancer Center (US), Arizona State University (US)
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon